600721.SHG Xinjiang Baihuacun Co Ltd
- Market cap
- CNY 3.88B
- P/E
- 168.3x
- P/B
- 4.58x
- ROE
- 2.8%
- Dividend yield
- 0.40%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600721.SHG undervalued?
Graham numberThe Graham number of Xinjiang Baihuacun Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xinjiang Baihuacun Co Ltd fundamental analysis
No fundamental analysis for Xinjiang Baihuacun Co Ltd yet.
Xinjiang Baihuacun Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xinjiang Baihuacun Co Ltd
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical science services, R&D project consulting, data management and statistical services, an…
Full company profileXinjiang Baihuacun Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xinjiang Baihuacun Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 745M | 420M | 419M | 262M | 84.5M | 281M | 350M | 369M | 386M | 388M | 307M |
| Gross Profit | -8.35M | 119M | 187M | 125M | -147M | 97.2M | 94.5M | 141M | 162M | 167M | 135M |
| Operating Income | 86.1M | -554M | -794M | 28.5M | -371M | 63.5M | -30.7M | 18.0M | 37.0M | 50.0M | 44.3M |
| EBITDA | 291M | -532M | -631M | 73.2M | -268M | 87.4M | -6.42M | 37.8M | 54.6M | 50.0M | 44.3M |
| Net Income | 139M | -564M | -675M | 34.4M | -320M | 59.8M | -34.8M | 13.0M | 41.5M | 40.7M | 22.4M |
| EPS | 0.49 | -1.41 | -1.69 | 0.09 | -0.82 | 0.16 | -0.09 | 0.03 | 0.11 | 0.11 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 2.78B | 2.03B | 1.25B | 1.29B | 975M | 982M | 1.00B | 1.06B | 1.11B | 1.10B | 1.08B |
| Total Liabilities | 486M | 300M | 329M | 337M | 351M | 296M | 334M | 355M | 356M | 294M | 280M |
| Shareholders' Equity | 2.29B | 1.72B | 914M | 955M | 619M | 681M | 667M | 707M | 759M | 802M | 803M |
| Cash & Short-term Investments | 341M | 125M | 100M | 96.1M | 55.6M | 86.9M | 136M | 202M | 272M | 299M | 56.5M |
| Total Debt | 83.8M | 22.2M | 17.4M | 20.0M | - | 6.30M | 2.33M | 1.13M | 3.93M | 2.25M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -108M | -50.3M | 80.6M | -6.80M | -23.3M | 34.7M | 53.2M | 62.1M | 80.3M | 32.9M | - |
| Capital Expenditure | 37.8M | 54.7M | 56.0M | 25.8M | 3.77M | 6.04M | 2.41M | 17.2M | 24.6M | 18.0M | 16.1M |
| Free Cash Flow | -146M | -105M | 24.5M | -32.6M | -27.1M | 28.7M | 50.8M | 44.8M | 55.7M | 14.9M | 11.0M |
| Ratios | |||||||||||
| ROE | 6.1% | -32.8% | -73.9% | 3.6% | -51.6% | 8.8% | -5.2% | 1.8% | 5.5% | 5.1% | 2.8% |
| ROA | 5.0% | -27.8% | -54.1% | 2.7% | -32.8% | 6.1% | -3.5% | 1.2% | 3.7% | 3.7% | 2.1% |
| Net Profit Margin | 18.7% | -134.5% | -161.1% | 13.1% | -378.3% | 21.3% | -9.9% | 3.5% | 10.8% | 10.5% | 7.3% |
| Debt to Equity | 0.04x | 0.01x | 0.02x | 0.02x | - | 0.01x | 0.00x | 0.00x | 0.01x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Xinjiang Baihuacun Co Ltd dividends
- Dividend yield
- 0.40%
- Forward dividend
- 0.04 CNY
- Payout ratio
- -
- Ex-dividend date
- May 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | CNY 121K | 0.00 | - |
| 2021 | CNY 39.2K | 0.00 | 0.1% |
| 2020 | CNY 752K | 0.00 | - |
| 2019 | CNY 894K | 0.00 | 2.6% |
| 2018 | CNY 1.04M | 0.00 | - |
| 2017 | CNY 2.81M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 11.0192:10 on Jan 23, 2008.
Who owns Xinjiang Baihuacun Co Ltd
- Insiders 38.99%
- Institutions 0.24%
- Public & others 60.77%
- Shares outstanding 385M
- Free float 264M
Xinjiang Baihuacun Co Ltd company profile
- Company name
- Xinjiang Baihuacun Co Ltd
- Ticker
- 600721.SHG
- ISIN
- CNE000000KQ1
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 3, 1996
- Sector
- Consumer Cyclical
- Industry
- Metals & Mining
- Employees
- 672
- Fiscal year end
- December
- Address
- No. 1, South Lane, Urumqi, China, 830002
- Phone
- 86 99 1235 6600
- Website
- xjbhc.net
About Xinjiang Baihuacun Co Ltd
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical science services, R&D project consulting, data management and statistical services, and third-party testing, which covers bioanalytical testing, packaging material compatibility, compound structure confirmation, quality studies, and base toxic impurity analysis. The company was formerly known as Xinjiang Baihuacun Co., Ltd. and changed its name to Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021. Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd was founded in 1959 and is based in Urumqi, China.
Xinjiang Baihuacun Co Ltd management
6- Mr. Hui HuangRotating GM & Director · born 1984
- Ms. Ziyun CaiChief Financial Officer · born 1973
- Mr. Zhengtian LuExecutive Deputy GM & Director · born 1964
- Mr. Yan XiaDeputy GM & Director · born 1980
- Ms. Qin Qin ZhaoSecretary to the Board · born 1983
- Tao YuAccounting Supervisor